Free Trial

Regencell Bioscience (RGC) Competitors

Regencell Bioscience logo
$17.41 -0.54 (-3.01%)
As of 10/17/2025 04:00 PM Eastern

RGC vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CALA

Should you be buying Regencell Bioscience stock or one of its competitors? The main competitors of Regencell Bioscience include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

Regencell Bioscience vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. Regencell Bioscience's average media sentiment score of 0.55 beat 180 Life Sciences' score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
180 Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Regencell Bioscience
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Regencell BioscienceN/AN/A-$4.30MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Regencell Bioscience N/A N/A N/A

Summary

Regencell Bioscience beats 180 Life Sciences on 4 of the 4 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGC vs. The Competition

MetricRegencell BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ Exchange
Market Cap$8.61BN/A$2.51B$10.54B
Dividend YieldN/AN/A2.50%4.81%
P/E RatioN/AN/A25.7827.13
Price / SalesN/AN/A105.60187.86
Price / CashN/AN/A44.3460.81
Price / Book870.50870.5035.806.52
Net Income-$4.30M-$4.30M$6.30M$276.93M
7 Day Performance3.57%3.57%0.96%1.93%
1 Month Performance11.32%11.32%-0.27%2.19%
1 Year PerformanceN/AN/A125.46%34.62%

Regencell Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGC
Regencell Bioscience
0.3997 of 5 stars
$17.41
-3.0%
N/AN/A$8.61BN/A0.0010News Coverage
ATNFW
180 Life Sciences
N/A$0.08
+33.6%
N/A+295.3%$0.00N/A0.007News Coverage
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AIMDW
Ainos
N/A$0.24
+5.1%
N/A+289.5%$0.00$110.87K0.0040News Coverage
Positive News
ALVOW
Alvotech
N/A$1.53
+16.6%
N/AN/A$0.00$560.10M0.004Gap Up
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.03
+24.8%
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.10
-1.1%
N/A+387.8%$0.00$39.19M0.0070Positive News
BTMDW
biote
N/A$0.01
+4.2%
N/A-98.6%$0.00$199.07M0.00N/AGap Down
BCTXW
BriaCell Therapeutics
N/A$0.04
+4.6%
N/A-81.5%$0.00N/A0.008Positive News
Short Interest ↑
CALA
Calithera Biosciences
N/A$0.00
-83.3%
N/AN/A$0.00N/A0.0060

Related Companies and Tools


This page (NASDAQ:RGC) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners